LUM and pancreatic ductal adenocarcinoma: In pancreatic ductal adenocarcinoma (PDAC) following surgical resection, high levels of lumican are correlated with decreased recurrence and prolonged patient survival, implicating lumican as an anti-oncogenic agent in this tissue-specific context.